Tirzepatide and SGLT2 Inhibitors Show an AF Signal
Can tirzepatide and SGLT2 inhibitors reduce atrial fibrillation burden? New data link metabolic therapy to fewer AF procedures, but trials must confirm it.
Wearable Monitoring in AF: Promising Outcome Results, Caveats
A 2026 meta-analysis reports fewer strokes, deaths, and hospitalizations with supervised wearable monitoring in diagnosed AF, with major caveats for consumer screening.